LOS ANGELES--(BUSINESS WIRE)--HemaCare Corporation (OTCBB:HEMA), a leader in cell and tissue collection, processing, and cell therapy solutions, today announced that it is supporting the 2016 CAR-TCR Summit to be hosted at the Hyatt Regency in Boston September 13-15th. This summit is the premiere meeting attended by 400 scientific and clinical leaders working on the development and clinical trial testing of cell therapies utilizing Chimeric Antigen Receptor (CAR) T-cell technologies to enable the patient’s immune system to fight deadly diseases like cancer. The CAR technology involves extracting T-cells from a patient (autologous) or a donor (allogeneic), expanding the cells and genetically modifying them to recognize a tumor-associated antigen. The CAR T-cells are then transferred to the patient, where they act to eradicate the tumor associated cells. Active preclinical research and clinical trials include CAR therapies for the treatment of acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma and multiple myeloma (MM).
HemaCare is the recognized apheresis leader in supporting autologous and allogeneic cell therapy, as well as supplying a broad array of hematopoietic tissue-derived cells for research, including bone marrow and umbilical cord blood. What sets us apart from others is our heritage as a transfusable collection center with over 38 years of experience operating an FDA-registered, cGMP/cGTP compliant donor center. HemaCare manages hundreds of reliable & recallable donors, who can meet various criteria for selection to be used for allogeneic cell therapy starting material globally.
“We actively seek opportunities to attend key scientific and clinical conferences to demonstrate our support through our capabilities to deliver primary cell expertise as well as a comprehensive portfolio of human primary hematopoietic cells, a necessary component for these researchers to develop and implement the innovations like CAR-T technology,” said Pete van der Wal, HemaCare’s Chief Executive Officer. “We understand the critical need researchers have for our products and specialized capabilities and will continue to dedicate our business to aid in the pursuit of the advancement of these technologies.”
View our product story at www.hemacare.com.
Since 1978, HemaCare Bioresearch Products & Services has been the trusted research partner of choice from concept to commercialization. Built on a 38-year history in apheresis collection, HemaCare is a leader in Cell and Tissue Collection, providing the high-quality biological material needed to ensure quality research outcomes that meet the unique needs of the scientific community. HemaCare’s expertise extends to serving biopharmaceutical firms with autologous and allogeneic collections used for Cell Therapy research, process development, and clinical trials. For more information please visit www.hemacare.com.